Inovio Pharmaceuticals, Inc. (INO) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you. Thank you. Thank you. Thank you. Good afternoon, ladies and gentlemen, and welcome to the Inovio First Quarter 2026 Financial Results Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Wednesday, May 13, 2026. I would now like to turn the conference over to Jenny Wilson. Please go ahead. Good afternoon, and thank you for joining the Inovio First Quarter 2026 Financial Results Conference Call. Joining me today on today's call are Dr. Jackie Shea, President and Chief Executive Officer, Dr. Mike Sumner, Chief Medical Officer, Steve Egge, Chief Commercial Officer, and Peter Keys, Chief Financial Officer. Today's call will review our corporate and financial information for the quarter ended March 31, 2026, as well as provide a general business update. Following prepared remarks, we will conduct a question and answer segment. During the call, we will be making forward-looking statements regarding future events and the future performance of the company. These statements relate to our business plans to develop Inovio's DNA medicines platform, including the FDA's ongoing review of our BLA for INO3107, including the October 30, 2026, PDUFA target date, and our yet to be scheduled meeting with the FDA to discuss eligibility for the accelerated approval program. Our belief that INO3107 fulfills the criteria for accelerated approval, The potential benefits of INO3107, including our belief that it has a positively differentiated product profile, and the potential to become the preferred product by patients and their physicians if approved. The an...